Page 77 - Read Online

Page 20 of 23 Casolino et al. Hepatoma Res 2021;7:76 https://dx.doi.org/10.20517/2394-5079.2021.79

25. Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic
cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer
2009;101:621-7. DOI PubMed PMC
26. Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a
comparative multicentre study in Japan. Br J Cancer 2010;103:469-74. DOI PubMed PMC
27. Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised
trials. Ann Oncol 2014;25:391-8. DOI PubMed
28. Sasaki T, Isayama H, Nakai Y, et al. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with
advanced biliary tract cancer. Cancer Chemother Pharmacol 2010;65:1101-7. DOI PubMed
29. Schinzari G, Rossi E, Mambella G, et al. First-line treatment of advanced biliary ducts carcinoma: a randomized phase II study
evaluating 5-FU/LV plus oxaliplatin (Folfox 4) versus 5-FU/LV (de Gramont Regimen). Anticancer Res 2017;37:5193-7. DOI
PubMed
30. Morizane C, Okusaka T, Mizusawa J, et al; members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical
Oncology Group (JCOG-HBPOG). Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent
biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol 2019;30:1950-8. DOI PubMed
31. Sakai D, Kanai M, Kobayashi S, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine,
cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). Ann Oncol 2018;29:viii205. DOI
32. Tella SH, Kommalapati A, Borad MJ, Mahipal A. Second-line therapies in advanced biliary tract cancers. Lancet Oncol 2020;21:e29-
41. DOI PubMed
33. Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann
Oncol 2014;25:2328-38. DOI PubMed
34. Belkouz A, de Vos-Geelen J, Mathôt RAA, et al. Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract
cancer: an open-label, single arm, phase 2 trial. Br J Cancer 2020;122:634-9. DOI PubMed PMC
35. Bridgewater J, Palmer D, Cunningham D, et al. Outcome of second-line chemotherapy for biliary tract cancer. Eur J Cancer
2013;49:1511. DOI PubMed
36. Leone F, Filippi R, Palloni A, et al. Prognostic factors in unresectable biliary tract cancer: a GICO (Gruppo Italiano
COlangiocarcinoma) retrospective analysis. Ann Oncol 2017;28:vi48. DOI
37. Brieau B, Dahan L, De Rycke Y, et al. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-
platinum combination: a large multicenter study by the Association des Gastro-Entérologues Oncologues. Cancer 2015;121:3290-7.
DOI PubMed
38. Schweitzer N, Kirstein MM, Kratzel AM, et al. Second-line chemotherapy in biliary tract cancer: outcome and prognostic factors.
Liver Int 2019;39:914-23. DOI PubMed
39. Takahara N, Nakai Y, Isayama H, et al. Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single
center, retrospective analysis of 294 cases. Invest New Drugs 2018;36:1093-102. DOI PubMed
40. Lamarca A, Ross P, Wasan HS, et al. Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03
clinical trials. J Natl Cancer Inst 2020;112:200-10. DOI PubMed
41. Salati M, Filippi R, Vivaldi C, et al. The prognostic nutritional index predicts survival and response to first-line chemotherapy in
advanced biliary cancer. Liver Int 2020;40:704-11. DOI PubMed
42. Filippi R, Leone F, Fornaro L, et al. Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-
world analysis. J Chemother 2021:1-10. DOI PubMed
43. Filippi R, Montagnani F, Lombardi P, et al. A prognostic model in patients with advanced biliary tract cancer receiving first-line
chemotherapy. Acta Oncol 2021;60:1317-24. DOI PubMed
44. Casadei-Gardini A, Filippi R, Rimini M, et al. Effects of metformin and vitamin D on clinical outcome in cholangiocarcinoma
patients. Oncology 2021;99:292-9. DOI PubMed
45. Rovesti G, Leone F, Brandi G, et al. Prognostic role of a new index tested in European and Korean advanced biliary tract cancer
patients: the PECS index. J Gastrointest Cancer 2021. DOI PubMed
46. Jusakul A, Cutcutache I, Yong CH, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of
cholangiocarcinoma. Cancer Discov 2017;7:1116-35. DOI PubMed PMC
47. Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas:
potential targets for intervention. Clin Cancer Res 2018;24:4154-61. DOI PubMed PMC
48. Chan-On W, Nairismägi ML, Ong CK, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-
infection-related bile duct cancers. Nat Genet 2013;45:1474-8. DOI PubMed
49. Welcome to the Pan-Cancer Atlas. Available from: https://www.cell.com/pb-assets/consortium/pancanceratlas/pancani3/index.html
[Last accessed on 16 Nov 2021].
50. Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet 2012;44:690-3.
DOI PubMed
51. Li M, Zhang Z, Li X, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the
ErbB pathway. Nat Genet 2014;46:872-6. DOI PubMed
52. Narayan RR, Creasy JM, Goldman DA, et al. Regional differences in gallbladder cancer pathogenesis: Insights from a multi-
institutional comparison of tumor mutations. Cancer 2019;125:575-85. DOI PubMed PMC
53. Zou S, Li J, Zhou H, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun 2014;5:5696. DOI PubMed